FDA Approves Drug to Treat MRSA, Other Skin Infections

The FDA has approved an antibacterial drug designed to treat adults with skin infections including Staphyloccous aureus (including MRSA) and Streptococcus pyogenes.

The intravenous drug, Dalvance, is the first drug designated as a Qualified Infectious Disease Product to receive FDA approval. It received this label under the Generating Antibiotic Incentives Now (GAIN) portion of the FDA Safety and Innovation Act, the agency's program for encouraging increased development and approval of new antibacterial drugs.

Dalvance is marketed by Chicago-based Durata Therapeutics.

To learn more, click here.